Last reviewed · How we verify
NCT05939167
Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage
Phase 1, PHASE2 trial testing mesenchymal stem cell in AIDS in 150 participants. Currently enrolling.
10 July 2027
Quick facts
| Lead sponsor | Cell Energy Life Sciences Group Co. LTD |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 10 December 2023 |
| Primary completion | 10 July 2027 |
| Estimated completion | 10 July 2028 |
| Sites | 4 locations across China |
Drugs / interventions tested
- mesenchymal stem cell
- saline
Conditions studied
- AIDS — all drugs for AIDS →
Sponsor
Cell Energy Life Sciences Group Co. LTD
Who can join
Adults 18 to 65, any sex, with AIDS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Therapeutic challenges in central nervous system viral infections: advancing mesenchymal stem cell-based strategies for treating neuroinflammation and promoting tissue repair.
Carbone-Schellman J, Fontecilla-Escobar J, Sales-Salinas N, Chaparro-Pico WF, et al · · 2025 · cited 1× · PMID 41235241 · DOI 10.3389/fimmu.2025.1677433
Verify or expand the search:
- PubMed search for NCT05939167
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of mesenchymal stem cell
Trials testing the same drug.
- NCT03209986 — Trial of Mesenchymal Stem Cell Transplantation in Decompensated Liver Cirrhosis · NA · unknown
Other recruiting trials for AIDS
Currently open trials in the same condition.
- NCT05373758 — A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa · NA · recruiting
- NCT06137196 — Risk Identification Factors for Pulmonary Function Impairment in AIDS Patients Recovered From Severe Pneumonia · recruiting
- NCT06145841 — Metagenomic Next-Generation Sequencing Guides Anti-Infection Strategies · recruiting
- NCT05988879 — Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients · recruiting
- NCT06045923 — Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV · recruiting
Other Cell Energy Life Sciences Group Co. LTD trials
Trials by the same sponsor.
- NCT06416709 — Stem Cell Treatment for Lung Injury Caused by Major Infectious Diseases · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05939167 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cell Energy Life Sciences Group Co. LTD
- Last refreshed: 12 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05939167.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing